Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma.
Adenocarcinoma, Sebaceous
/ diagnosis
Biomarkers, Tumor
/ metabolism
Carcinoma, Basal Cell
/ metabolism
Gene Amplification
Humans
Male
Middle Aged
Receptor, Fibroblast Growth Factor, Type 2
/ metabolism
Sebaceous Gland Neoplasms
/ diagnosis
Skin Neoplasms
/ metabolism
Thymoma
/ diagnosis
Thymus Neoplasms
/ metabolism
Adipophilin
BRCA2
FGFR2
Sebaceous carcinoma
Thymus carcinoma
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
02
06
2019
accepted:
02
08
2019
revised:
30
07
2019
pubmed:
12
8
2019
medline:
26
2
2020
entrez:
12
8
2019
Statut:
ppublish
Résumé
Our aim was to investigate sebaceous differentiation in thymus tumours and to identify new actionable genomic alterations. To this end we screened 35 normal and 23 hyperplastic thymuses, 127 thymomas and 41 thymic carcinomas for the presence of sebaceous differentiation as defined by morphology and expression of adipophilin and androgen receptor (AR). One primary thymic carcinoma showed morphology of sebaceous carcinomas (keratinizing and foam cells, calcifications, giant cells), a strong expression of adipophilin and AR together with squamous markers. NGS revealed high-level amplification of fibroblast growth factor receptor 2 (FGFR2). In thymuses and thymomas, no cells with sebaceous morphology were present. Occasionally, macrophages or epithelial cells showed adipophilin-positivity, however, without co-expression of AR. Thymic sebaceous carcinoma should be considered if a thymic carcinoma shows clear or foamy features. Testing for FGFR2 amplification might be warranted when searching for actionable genomic alterations in sebaceous carcinomas in the mediastinum and in other locations.
Identifiants
pubmed: 31401665
doi: 10.1007/s00428-019-02644-3
pii: 10.1007/s00428-019-02644-3
doi:
Substances chimiques
Biomarkers, Tumor
0
FGFR2 protein, human
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 2
EC 2.7.10.1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
323-327Références
Virchows Arch. 2018 May;472(5):877-880
pubmed: 29556777
Int J Surg Pathol. 2013 Oct;21(5):526-30
pubmed: 23358435
Histopathology. 2019 Sep;75(3):431-436
pubmed: 31050844
Nat Commun. 2018 May 14;9(1):1894
pubmed: 29760388
Hum Pathol. 2019 Apr;86:124-128
pubmed: 30537491
Expert Rev Anticancer Ther. 2018 Sep;18(9):861-872
pubmed: 29936878
Hum Pathol. 1984 Apr;15(4):341-3
pubmed: 6714965
Head Neck Pathol. 2018 Mar;12(1):118-122
pubmed: 28721661
Nat Rev Clin Oncol. 2019 Feb;16(2):105-122
pubmed: 30367139
Cancer. 2011 Oct 1;117(19):4396-405
pubmed: 21437890
J Pathol. 2016 Sep;240(1):84-95
pubmed: 27287813
Histopathology. 2018 Oct;73(4):585-592
pubmed: 29856905
Gynecol Oncol Rep. 2018 Aug 29;26:37-40
pubmed: 30225334
Intern Med. 2015;54(3):351-2
pubmed: 25748747
Am J Surg Pathol. 2002 Jun;26(6):795-8
pubmed: 12023586